Here is the portion of the EXAS CC Q&A Transcript that deals with Genomic Health.
Derik De Bruin, BofA Merrill Lynch, Research Division - MD of Equity Research [4]
Any news on the Genomic Health business, any specific upcoming milestones and things that we should be looking for in terms of clinical data releases for the next year?
--------------------------------------------------------------------------------
Jeffrey T. Elliott, Exact Sciences Corporation - CFO [5]
--------------------------------------------------------------------------------
Yes. So that business continues to perform very well, which is exciting. Keep in mind that the second half of 2019 was arguably the strongest period of that company's history, right? And that came at a time during the acquisition announcement and the acquisition close. The team at Genomic Health delivered 2 of its very strongest quarters. So we entered 2020 with very good momentum.
Really, a lot of this momentum stems from the continued benefit of the TAILORx study, which is now almost 2 years old and as well as the team is a really high-quality team. Top to bottom, a really high-quality team. So I would expect 2020 to be another good year of execution. When I look at the 3 main components of that business, the U.S. breast franchise, we expect mid-single-digit growth there. And that business, now you are 2 years post TAILORx, so some moderation in the growth was to be expected.
Internationally, again, a really strong team, which will provide a valuable foundation for years to come. As we bring new tests to market, expect strong double-digit growth internationally. And prostate, prostate ended the year last year with very good momentum. Strong -- we expect strong double-digit growth in that business. And even -- what you're seeing is even stronger unit growth and volume growth, given improving reimbursement dynamics.
--------------------------------------------------------------------------------
Daniel Henry Macek-Alwell, Stifel, Nicolaus & Company, Incorporated, Research Division - Associate [40]
--------------------------------------------------------------------------------
Got you. Okay. And then one last quick one. Just switching over to Genomic Health, the Oncotype DX in terms of reimbursement in Germany and France, if you could just provide the latest there.
--------------------------------------------------------------------------------
Jeffrey T. Elliott, Exact Sciences Corporation - CFO [41]
--------------------------------------------------------------------------------
Yes. So there's some exciting news in Germany last year with the establishment of the reimbursement code, so that is moving forward. And we expect Germany to be one of the more major growth drivers for that business.
Really, this all stems from the TAILORX study, which, as you know, published back in 2018. So that study has led to improving reimbursement globally, and Germany is one of the bigger drivers this year. I would say, France, as we've said before, does lag that a bit. But given the strength of the evidence here, we expect reimbursement to continue to improve for years to come.
--------------------------------------------------------------------------------
Presently, BCART is involved with the international (starting in EU) launch of OncoTypeDX Breast assay on Idylla and the OncoTypeDX Prostate assay that is being developed. With a lot of reading between the lines, the picture is bright for the Idylla launch of both the Breast and Prostate Assays.
FL